LivaNova

After an extraordinary 47-year career, Walter Poprawa is retiring, leaving behind an inspiring legacy of innovation, leadership, and lasting relationships. Walter’s journey with LivaNova began in 1977 and he played a pivotal role in advancing the cardiopulmonary industry in Canada. “Walter is one of the most customer-centric representatives I have ever had the pleasure of working with,” said Janet Stewart, National Sales Director, Canada, Cardiopulmonary. In honor of his career, a special celebration was held to commemorate his remarkable contributions, and the Markham Training Room will now bear Walter’s name. Congratulations on your retirement, Walter. #WeAreLivaNova #WorkThatMatters

The RECOVER clinical study has shown meaningful benefits of LivaNova’s VNS Therapy™ System in select secondary endpoints for unipolar patients with treatment-resistant depression (TRD). Researchers’ findings support the use of VNS Therapy to deliver vagus nerve stimulation (VNS) in patients with TRD. The journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the study. Overall, the articles concluded that active VNS Therapy, as compared with a no-stimulation control (or sham VNS Therapy), safely and effectively demonstrated clinically meaningful therapeutic effects on depressive symptoms and positive effects on quality of life and daily function. “Participants in the trial had severe, refractory depression that could not be treated effectively with other FDA-approved treatments, and most have had large portions of their lives profoundly negatively impacted by depression,” said Charles Conway, MD, director of the Washington University Resistant Mood Disorders Center at Washington University School of Medicine in St. Louis. Conway is the study's lead investigator. “For this sample of markedly ill TRD participants, I am encouraged by the findings, which revealed that active VNS performed better than sham VNS treatment in all measures, and that active VNS demonstrated clinically meaningful, safe therapeutic effects. Multiple clinician, patient, and independent observer ratings separated between the active and sham unipolar arms.” Three subsequent, supportive manuscripts will feature outcomes from in-depth data analyses on select secondary endpoints. The totality of data presented in these five complementary articles will serve as the basis for LivaNova’s formal request to the U.S. Centers for Medicare and Medicaid Services (CMS) for VNS Therapy coverage. See the full press release here: https://livn.info/4gknuei

What Does Seizure Freedom Look Like After the Addition of VNS Therapy™ in People with Drug-Resistant Epilepsy? A recent analysis by Tani and colleagues published in the journal Epilepsia Open investigated the effectiveness of adjunctive vagus nerve stimulation in achieving at least 1-year without seizures for patients with drug-resistant epilepsy (DRE) in Japan. After 3 years of VNS Therapy, 10.7% and 25.3% of patients had experienced 12 consecutive months of seizure freedom from all seizures and focal seizures, respectively. In addition, the median seizure-free period for all seizures and focal seizures was 19.4 and 25.1 months. “This is an important insight which provides patients, their families, and care providers a better understanding of the durability of the effect of anti-seizure treatments like adjunctive VNS Therapy,” said Maxine Dibué, PhD, Director of Medical Affairs, Neuromodulation International at LivaNova PLC, one of the two primary authors of the study. Professor Haruhiko Kishima, chairman of the Department of Neurosurgery at Osaka University Graduate School of Medicine and senior author of the paper, adds “Clinicians who treat patients with epilepsy know that uncontrolled or severe seizures like tonic-clonic seizures, place patients at an increased risk for injuries and for sudden unexpected death in epilepsy (SUDEP).*” “This research emphasizes the potential of VNS Therapy as a valuable adjunctive therapy for managing DRE, offering hope for improved daily living and sustainable seizure control. The study also underscores the importance of further investigating seizure-free periods of individual seizure types and their association with patient-reported quality of life"- Naoki Tani, MD, PhD neurosurgeon at Osaka University and one of the two primary authors. The full publication is available at: Epilepsia Open® - Tani, N., Dibué, M., Verner, R., Nishikawa, S. M., Gordon, C., Kawai, K., & Kishima, H. (2024). One-year seizure freedom and quality of life in patients with drug-resistant epilepsy receiving adjunctive vagus nerve stimulation in Japan. Epilepsia open, 10.1002/epi4.13025. Advance online publication. https://livn.info/3B0cDH6 View Important Safety Information at: livn.info/VNSisi VNS Therapy indications may vary by geographic location. Please consult your local labeling for further information. * See https://bit.ly/4igB4R7 and https://bit.ly/3Bev9vi

A LivaNova Cardiopulmonary technical service team recently hosted a significant international training event in Dubai. The training focused on equipping engineers with specialized expertise on the S5 Heart-Lung Machine, Essenz Perfusion System, and Essenz Patient Monitor to meet growing demand across the Middle East and Africa. The event brought together engineers from nine countries, with 20 participants successfully completing the certification process. Initiatives like this empower service professionals with the knowledge and skills necessary to maintain safe and reliable devices. A special thank you to the expert trainers who led the sessions: Mohammad Al-Watyan, Christina Rumswinkel, Olaf Hörl, and Dörte Schneider.

We are pleased to announce that LivaNova India has officially been certified as a “Great Place to Work.” This certification, granted by the globally renowned Great Place to Work, places the company among the best workplaces in Asia, showcasing its leadership in workplace excellence and employee experience. “This certification isn’t just a badge of honor,” says Adriana Visbal, HR Manager for ANZ & South Asia. “It’s a reflection of the hard work and culture our team has built together. It inspires us to continue raising the bar for excellence and innovation.” This is a defining moment for the India team, recognizing its ongoing commitment to nurture a supportive and thriving workplace culture. Congratulations to the entire team! #WeAreLivaNova #WorkThatMatters

Sharing some lessons I've learned in how to promote an Innovative culture and operating model. I'd love to hear how you're doing the same. #innovation at LivaNova

At the American Epilepsy Society 2024 Annual Meeting, Dec. 6-10 in Los Angeles, we will present in-progress data from our contemporary real-world evidence study, “CORE-VNS: Comprehensive Outcomes Registry in Subjects With Epilepsy Treated With Vagus Nerve Stimulation Therapy.” Related presentations will take place from 12-2 pm PST on Dec. 7-8. During those same times, additional clinical and health economic research will be displayed. These posters showcase the work of LivaNova employees and/or independent investigators and demonstrate our enduring commitment to advance epilepsy research and support a deeper understanding of the non-pharmacological treatment of seizures. See the titles and presenters of all of our posters in our press release: https://livn.info/aes24

We are thrilled to announce the launch of the new LivaNova Cardiopulmonary LinkedIn page! If you're a perfusionist or a professional in the cardiopulmonary space, this is the perfect place for you. This page will serve as our central hub for the latest news, advancements, and discussions in the field. We invite you to join our community to stay up to date on our globally-renowned product line and upcoming innovations. Don't miss out – follow us today! https://livn.info/CPLI #LivaNova #Cardiopulmonary #NewEraOfPerfusion #Perfusionists #HealthcareInnovation

"Being at LivaNova is a good combination of challenging topics that I think would interest any engineer. It gives me a sense of purpose," said Beatrice Ferrante, an Industrial Engineer in our Cardiopulmonary Business Unit. #WomenInMedtech #WeAreLivaNova #WorkThatMatters

Check out the latest episode of The Balancing Act featuring VNS Therapy™ for drug-resistant epilepsy. VNS Therapy™ is an add-on neuromodulation treatment designed for people with drug-resistant epilepsy 4 years of age and older with focal seizures. See important safety information at www.vnstherapy.com/safety